North American Report

Short Bowel Syndrome Pipeline, Clinical Trials, Emerging Therapies and Key pharma players involved by DelveInsight | Zealand Pharma, Therachon AG, VectivBio, Takeda and Others

 Breaking News
  • No posts were found

Short Bowel Syndrome Pipeline, Clinical Trials, Emerging Therapies and Key pharma players involved by DelveInsight | Zealand Pharma, Therachon AG, VectivBio, Takeda and Others

May 25
15:58 2021
Short Bowel Syndrome Pipeline, Clinical Trials, Emerging Therapies and Key pharma players involved by DelveInsight | Zealand Pharma, Therachon AG, VectivBio, Takeda and Others

Short Bowel Syndrome Pipeline

Short Bowel Syndrome Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Short Bowel Syndrome market. A detailed picture of the Short Bowel Syndrome pipeline landscape is provided, which includes the disease overview and Short Bowel Syndrome treatment guidelines.

The assessment part of the report embraces in-depth Short Bowel Syndrome commercial assessment and clinical assessment of the Short Bowel Syndrome pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Short Bowel Syndrome collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Some of the key companies working on Short bowel syndrome Market are:

  • Zealand Pharma
  • Therachon AG
  • VectivBio
  • Takeda
  • NPS Pharmaceuticals (Acquired by Shire Plc.)
  • OxThera
  • And Many Others.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

 

Short Bowel Syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine.

Short Bowel Syndrome is generally broken down into individuals in whom the disorder is acquired during life and newborns in which the disorder is present at birth (congenital). Acquired short bowel syndrome is more common than the congenital form of the disorder. The specific symptoms and severity of Short Bowel Syndrome vary from one person to another. Diarrhea is common, often severe and can cause dehydration, which can even be life-threatening. Short Bowel Syndrome can lead to malnutrition, unintended weight loss, and additional symptoms may be due to the loss of essential vitamins and minerals.

Short Bowel Syndrome is most commonly associated with surgical removal (resection) of half or more of the small intestine. Such surgery is performed to treat intestinal diseases such as Crohn’s disease, injury or trauma to the small bowel, or congenital birth defects. In some cases, newborns can be born with a shortened bowel that is present at birth (congenital short bowel syndrome). The exact cause of a short bowel in these cases is not fully understood and several different theories have been proposed. More research is necessary to determine what factors ultimately lead to congenital short bowel syndrome.

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

 

The launch of the emerging therapies is expected to significantly impact the Short bowel syndrome   treatment scenario in the upcoming years:-

Short bowel syndrome Drugs Covered:

  • Glepaglutide
  • Apraglutide
  • GLP-1/GLP-2 dual agonist (ZP7570)
  • Gattex (teduglutide)
  • And Many Others.

 

Request a Free Sample Report @  https://www.delveinsight.com/sample-request/short-bowel-syndrome-pipeline-insight

 

Key Questions Short Bowel Syndrome Market are:

  • What are the current options for Short Bowel Syndrome treatment?
  • How many companies are developing therapies for the treatment of Short Bowel Syndrome
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Short Bowel Syndrome?
  • How many Short Bowel Syndrome emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Short Bowel Syndrome?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies? 
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Short Bowel Syndrome market? 
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Short Bowel Syndrome?  
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Short Bowel Syndrome therapies? 
  • What are the clinical studies going on for Short Bowel Syndrome and their status?
  • What are the results of the clinical studies and their safety and efficacy? 
  • What are the key designations that have been granted for the emerging therapies for Short Bowel Syndrome
  • How many patents are granted and pending for the emerging therapies for the treatment of Short Bowel Syndrome

 

Request for free Sample Report: https://www.delveinsight.com/sample-request/short-bowel-syndrome-market

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/short-bowel-syndrome-market